Absorption of orally disintegrating carbidopa-levodopa requires intact small bowel function.
Iyer
Sanjay S
SS
Department of Neurology, Medical College of Georgia, Augusta, GA 30912, USA.
Morgan
John C
JC
Sethi
Kapil D
KD
D000284:Administration, Oral; D000368:Aged; D002230:Carbidopa / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D018450:Disease Progression; D015259:Dopamine Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007418:Intestinal Pseudo-Obstruction / Q000209:etiology / Q000503:physiopathology*; D007421:Intestine, Small / Q000187:drug effects* / Q000503:physiopathology; D007980:Levodopa / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy*; D018579:Patient Selection; D013375:Substance Withdrawal Syndrome / Q000209:etiology / Q000503:physiopathology; D017211:Treatment Failure
D015259:Dopamine Agents; D004338:Drug Combinations; D007980:Levodopa; D002230:Carbidopa